NPS downgraded to market perform by JMP

NPS Pharmaceuticals, Inc. was downgraded to market perform from market outperform by JMP Securities analyst Charles C. Duncan based on the timing of U.S. Preos approval and uncertainty surrounding risk ratio. The company's first-quarter results beat JMP's and consensus expectations on top and bottom lines. Shares of the Salt Lake City biotechnology company were down $3.22, or 39.22%, at $4.99 on volume of 10,698,635 shares versus the three-month running average of 1,190,180 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.